Search PubMed⌕ Search

Biomedical subjects

V Bonomini

Publications and source records attributed to V Bonomini.

At least 127 records · Page 7Linked to original sources
PubMed1985

Short-term, high-dose muzolimine treatment in patients with chronic renal failure and acute fluid retention.

Muzolimine, the new sulphonamide-free loop-diuretic with both high ceiling and long-lasting activities, was tested in 21 adult patients with chronic renal failure (CRF) (creatinine clearance ranging from 30 to 5 ml/min) and acute fluid overload. Low-protein diet and individual drug therapy were unchanged throughout the study. All patients received a single oral dose of 240 mg of muzolimine for 4 or 6 consecutive days depending on individual response. Clinical status, diuresis, body weight, blood and urine chemistry were recorded daily. In 19 out of 21 patients muzolimine treatment induced reversal of edema and congestive heart failure and a satisfactory fluid balance was achieved. Only two patients did not respond to diuretic treatment and required dialysis to control fluid balance and azotemia. In responsive patients diuresis increased by 50-100% and no rebound antidiuresis was observed after drug withdrawal. Body weight decreased meanly by 9%. No significant change occurred in serum concentration of K throughout the study, even in the 11 patients on digoxin. Except for a slight decrease of serum Cl by the end of treatment, no significant change in serum electrolytes was recorded. No effect was observed on blood glucose, urea and creatinine clearance whereas a slight increase of serum uric acid was recorded. Urinary lysozyme and gamma-GT were similar before and after the trial. Apart from a single case of muscle cramps, no significant side-effects were recorded. In conclusion, the present results indicate that short-term, high-dose oral muzolimine treatment is effective and safe in most patients with advanced CRF and acute fluid retention.

Adult↗
PubMed1984

Present status of hemoperfusion/hemodialysis in Italy.

The use of charcoal hemoperfusion in the treatment of chronic renal failure has been proposed and applied by several authors. The availability of coating membranes of increased biocompatibility currently allows a safer and wider use of this purifying technique. It has been recently demonstrated that long-term treatment with combined hemodialysis/hemoperfusion yields an improvement of certain dialysis-resistant uremic signs in patients on regular dialysis treatment, while in selected patients it affords a marked reduction (up to one-third) in the overall time of treatment per week. The tolerance of long-term treatment is good. In line with these findings, a multicenter study has been carried out in Italy with two main aims: (1) to see whether long-term treatment with charcoal hemoperfusion is really safe and substantially free from side effects; (2) to verify in a larger and more varied population of patients whether such long-term treatment actually improves certain uremic signs persisting despite adequate dialysis treatment. A third phase of the multicentric study (reducing the weekly time of treatment) is currently being worked on. Five nephrology and dialysis departments took part in the study: in Bologna, Rome, Chieti, Ancona, and Lecce.

Clinical Trials as Topic↗
PubMed1984

Long-term patient and renal prognosis in acute renal failure.

A long-term clinicomorphological study in 227 patients with acute renal failure due to intrinsic renal damage shows the clinical value of renal biopsy for assessing treatment and predicting prognosis. Early morphological diagnosis enables appropriate therapeutic measures, which play their part in patient survival and renal survival. Present long-term results show that 5 years after the acute episode, chronic renal failure may be expected to occur in about 50% of cases with acute renal failure due to glomerular and vascular injuries. Tubulointerstitial lesions are associated with definitely better long-term prognosis.

Acute Kidney Injury↗
PubMed1984

Early dialysis.

Explore the source record for details and available documents.

Humans↗
PubMed1984

Effect of plasmapheresis on cellular immunity abnormalities in patients with systemic lupus erythematosus.

The effect of plasmapheresis on cellular immunity was studied in 10 patients with active lupus erythematosus (SLE) by evaluating before and after treatment the percentage of E-rosette forming cells (E-RFC), the inhibitory effect of patients' sera on rosette formation by normal lymphocytes, the Con A-induced suppressor activity and T-cell subsets studied by means of monoclonal antibodies. After plasmapheresis a significant improvement was observed in E-rosette formation and in Con A-induced suppressor activity, along with a marked reduction in the inhibitory effect of patients' sera on rosette formation. No change was observed in the number and percentage of T-cell subsets. These findings suggest that plasmapheresis may remove some circulating factors responsible for the immunoregulatory T-cell dysfunction observed in patients with active SLE.

Adolescent↗
PubMed1983

Detection of lymphocyte subsets in renal graft biopsy by monoclonal antibodies.

Monoclonal antibodies were used to study infiltrating cell subpopulations in 12 graft biopsy specimens taken from 12 patients during rejection episodes. A preponderance of T lymphocytes in the renal interstitium was observed in most cases, with a higher percentage of suppressor/cytotoxic cells. No correlation was documented between the type and severity of rejection and the percentage of the various infiltrating cells.

Adolescent↗
PubMed1983

Effects of renal substitutive programs on amino acid patterns in chronic uremia.

Abnormalities in the amino acid patterns are a constant finding in chronic renal failure and can be regarded as one of the typical biochemical alterations of uremia. This paper evaluates the long-term effects of various artificial substitutive treatments and renal transplantation on plasma and tissue amino acid patterns in chronically uremic patients. Fifty-three patients were included in the study: 35 on artificial treatments (9 on hemodialysis, 9 on hemofiltration, 4 on hemoperfusion, 6 on continuous ambulatory peritoneal dialysis, and 7 on intermittent peritoneal dialysis) and 18 with well-functioning renal transplants. Complete plasma aminograms were performed in all patients before starting the treatment, and repeated every 3 months up to 1 year (artificial therapies) and 3 years (renal transplantation). The amino acid composition of the bone was also determined in 8 dialysis patients and 9 transplant patients. None of the artificial therapies was associated with normal plasma patterns either in the short- or in the long-term, whereas successful renal transplantation led to normalization of the plasma profile within 2 to 4 months in all patients. However, bone amino acid composition remained altered both in artificially treated and in transplanted patients.

Adolescent↗